When Kristine Dalton (OD '07, MSc '10) first stepped into a meeting on Paralympic classification more than a decade ago, she ...

Science Corp. raised $230 million as it awaits a decision from the FDA on PRIMA, its wireless retinal implant.

Our role is to carefully screen each patient and help them choose the solution that best matches their lifestyle.”— Dr.

A tiny wireless implant placed under the retina helped many people with advanced age related macular degeneration regain useful central vision in a clinical trial. After one year, most participants ...

Science has added a whole lot more cash to the bank, bringing in an impressive $230 million in its latest raise. | Science has added a whole lot more cash to the bank, bringing in an impressive $230 ...

Acuity (AYI) is back on investors’ radars after recent trading left the shares giving up ground over the past month and past 3 months, prompting fresh attention on its fundamentals. See our latest ...

Label expansion strategy -- The company is actively pursuing a broad label for Tadaraben to include all Stargardt disease ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, ...

The medical board performed comprehensive tests, including optical coherence tomography on both of Imran's eyes ...

Thank you, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals, Inc.'s Fourth Quarter and Full Year 2025 financial results and recent corporate developments ...

Biotechnology firm Ocugen has successfully completed patient enrollment for its pivotal Phase 3 clinical trial, known as liMeliGhT, marking a significant step f ...

Key points A 4-year-old boy presented to our urgent ophthalmology clinic for photophobia and persistent eye rubbing. He had been born at 39 weeks via Cesarean delivery, without complications. Prenatal ...